Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia
- Alfonso Quintás-Cardama(corresponding author),
- Hagop M. Kantarjian,
- University of Texas MD Anderson Cancer Center,
- University of Texas Health Science Center at Houston
Scholary Output:
Contribution to journal
Review article
Research
Peer-reviewOpen access
Abstract
<p>Background: Although the vast majority of patients with chronic myeloid leukemia (CML) respond to the tyrosine kinase inhibitor (TKI) imatinib mesylate, resistance might occur de novo or during treatment. Methods: The authors reviewed the known mechanisms of primary and secondary resistance to imatinib and other TKIs used in the management of CML. Results: Mutations within the kinase domain of BCR-ABLI account for 30% to 40% of cases of imatinib resistance. Other mechanisms include BCR-ABLI amplification, overexpression of the SRC family of kinases, and pharmacokinetic and pharmacodynamic factors. Conclusions: Although not all resistance mechanisms have been identified and understood, several agents based on the known mechanisms have already been designed and developed and are beginning clinical trials.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 122-131 (10 pages)Journal (Volume, Issue Number)
Cancer Control (Volume 16, Issue 2)Publication milestones
- Published - 04/2009
Publication status
Published - 04/2009
ISSN
1073-2748Publication IDs
- Scopus: 65249185560
- PubMed: 19337198
Publication metrics
Metrics
SciVal
citations
167
SciVal
FWCI
4.55
SciVal
Author count
3
SciVal
Paper percentile
98
SciVal
Top percentile
5
Fractional count
1
Fractional count
0.33
Fractional count
2
Fractional count
0.67
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
168
Mentions
1
Citation count
219
